JCO Global Oncology最新文献

{"title":"Understanding Barriers to Clinical Cancer Research in the Asia-Pacific.","authors":"Rashid N Lui, Jimmy Billod, Sophia Frentzas, Hang Hoang, Vanessa Eaton, Xiudong Jennifer Lei, Elizabeth Garrett-Mayer, David Goldstein, Rebecca Dent, Melvin L K Chua","doi":"10.1200/GO-25-00145","DOIUrl":"https://doi.org/10.1200/GO-25-00145","url":null,"abstract":"<p><strong>Purpose: </strong>Despite the large cancer burden in the Asia-Pacific (APAC) region, there are significant challenges in conducting clinical research for health care professionals (HCPs) in the region, with gross disparities in access to clinical trials for patients. We set out to assess these potential barriers and to provide a basis to formulate strategies to address these challenges.</p><p><strong>Patients and methods: </strong>We conducted an online cross-sectional survey of HCPs practicing in oncology-related fields from the APAC. The survey's questions were framed around the respondents' demographics and other information including age, sex, affiliation, years of training, involvement with research, and attitude toward international cancer societies. Respondents were also analyzed by their country's income level according to World Bank criteria.</p><p><strong>Results: </strong>From May to July 2022, a total of 300 responses were received from 21 APAC countries and regions. Overall, the top five potential barriers that were identified include competing demands (88.5%), lack of financial support (85.9%), health care access issues for patients (75.3%), lack of research environment and infrastructure (72.2%), and lack of expertise of staff (68.1%). For these barriers, the main significant differences that were found between high-income countries and lower-middle-income countries include the lack of financial support, research environment and infrastructure, expertise, and health care access.</p><p><strong>Conclusion: </strong>In this large, cross-sectional survey exploring the research and trial landscape in the APAC, we found various common and specific challenges affecting different countries and regions, thus emphasizing the importance of targeted measures in addressing these barriers. We hope that these findings will inform future planning and engagement efforts to improve access to trials and empower research in the region.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500145"},"PeriodicalIF":3.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and Prognosis of Systemic Chemotherapy for Unresectable Malignant Apocrine and Eccrine Tumors: A Real-World Multicenter Retrospective Study.","authors":"Shintaro Saito, Masahito Yasuda, Takeshi Araki, Dai Ogata, Masazumi Onishi, Shusuke Yoshikawa, Yutaka Inaba, Etsuko Okada, Junji Kato, Tatsuya Takenouchi, Yasuhiro Fujisawa, Hiroyuki Irie, Yukiko Kiniwa, Shuji Yamamura, Taiki Isei, Takayuki Konno, Ikko Muto, Yosuke Yamamoto, Takeo Maekawa, Ryo Tanaka, Takuya Omine, Jun Asai, Shiro Iino, Motoki Nakamura, Yasuhiro Nakamura, Kotaro Nagase, Takeshi Kato, Yutaka Kuwatsuka, Takeru Funakoshi, Sei-Ichiro Motegi","doi":"10.1200/GO-25-00180","DOIUrl":"10.1200/GO-25-00180","url":null,"abstract":"<p><strong>Purpose: </strong>Malignant apocrine and eccrine tumors (MAETs) are extremely rare cutaneous adnexal malignancies, accounting for only 0.005%-0.01% of all skin tumors. These tumors are highly metastatic, and evidence regarding optimal chemotherapy and prognostic outcomes remains limited. This study aimed to evaluate the efficacy of systemic chemotherapy and overall prognosis in Japanese patients with unresectable MAETs.</p><p><strong>Patients and methods: </strong>We conducted a retrospective, multicenter study involving 81 patients with unresectable MAETs treated at 27 institutions across Japan. Patients received one of three primary chemotherapy regimens: platinum-based (cisplatin or carboplatin), taxane-based (docetaxel or paclitaxel), or TS-1 (tegafur/gimeracil/oteracil). Patient demographics, objective response rates (ORRs), overall survival (OS), and progression-free survival were assessed. Survival curves were estimated using the Kaplan-Meier method.</p><p><strong>Results: </strong>The estimated ORRs for the platinum-based, taxane-based, and TS-1 groups were 37.0%, 25.0%, and 22.2%, respectively, with no statistically significant differences among them (<i>P</i> = .527). The median OS and 5-year OS rate for the entire cohort were 29.0 months and 34.0%, respectively. The median OS and 5-year OS rates by regimen were as follows: platinum-based, 29.0 months and 36.2%; taxane-based, 22.0 months and 39.7%; and TS-1, 30.0 months and 13.9%, with no significant differences observed (<i>P</i> = .907). In addition, there were no significant differences in ORR or OS between patients receiving combined chemoradiotherapy and those receiving chemotherapy alone.</p><p><strong>Conclusion: </strong>No single chemotherapeutic regimen demonstrated superior efficacy in patients with unresectable MAETs. These findings highlight the need for further investigations using larger, prospective cohorts and multidisciplinary approaches to establish optimal therapeutic strategies for this rare malignancy.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500180"},"PeriodicalIF":3.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145053398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Point-of-Care Urine Metabolomics Test to Diagnose Colorectal Cancers in Low- and Middle-Income Countries: A Pilot Controlled Trial in Southwestern Nigeria.","authors":"Adeleye A Adeomi, Olusegun I Alatise, David Wishart, Scott MacKay, Olalekan Olasehinde, Funmilola Wuraola, Adewale Adisa, Tajudeen Mohammed, Adewale Aderounmu, Omolade Adefolabi Betiku, Oluwatosin Zainab Omoyiola, Adeoluwa Oluwaseyi Adeleye, Samson Oluwagbemiga Ogunleye, Olusegun Joshua Babatunde, Oluwabusayomi Roseline Ademakinwa, Israel Adeyemi Owoade, Jacob Mobolaji, Cristina Olcese, Rivka Kahn, Naqiya Rahil Choonawala, Grace Fitzgerald, H Dean Hosgood, T Peter Kingham","doi":"10.1200/GO-25-00062","DOIUrl":"https://doi.org/10.1200/GO-25-00062","url":null,"abstract":"<p><strong>Purpose: </strong>To test the feasibility of a point-of-care (POC) real-time urine metabolomics test, evaluate its validity in diagnosing colorectal cancer (CRC) among at-risk patients, and assess the willingness of patients in Southwestern Nigeria to use and pay for the test.</p><p><strong>Methods: </strong>This was a pilot-controlled trial carried out among 72 patients (34 cases and 38 controls) in southwestern Nigeria. The cases were those with histopathological diagnosis of CRC while controls were at-risk adults. The POC biosensor used a disposable chip and can be connected to a smart device using Bluetooth, and reported if the patient's urine contained metabolites consistent with CRC. We assessed validity of the test using sensitivity, specificity, positive predictive value (PPV) and negative predictive values (NPV), and prespecified a specificity of 50% with a goal of ≥80% sensitivity to estimate the potential of the test to half the referrals to colonoscopy. Additionally, we assessed perception toward the test and willingness to uptake the urine test using structured questionnaires.</p><p><strong>Results: </strong>The overall sensitivity, specificity, PPV, and NPV for all respondents were 91.18%, 81.58%, 81.58%, and 91.18% respectively, with an area under the receiver operating characteristic curve of 0.86. With specificity fixed at 50%, the overall sensitivity for all respondents was 94.5%, and all stratifications had sensitivity >90%. Overall, 70 (98.6%) were satisfied with the urine-based CRC screening, and respondents were willing to pay a mean amount of 8,008.20 Naira (about $5.2 US dollars) for the test.</p><p><strong>Conclusion: </strong>Our urine metabolite early diagnosis POC test met our predetermined criteria for success and had high acceptance rates among Nigerian patients, supporting a future multi-institutional implementation trial assessing our ability to scale up utilization.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500062"},"PeriodicalIF":3.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144794463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Training Non-Oncologist Healthcare Providers to Manage Oral Endocrine Therapy for Breast Cancer.","authors":"Aimable Ndayishimiye, Alexandra Fehr, Vestine Rugema, Vincent Kalumire Cubaka, Jean Claude Niyibizi, Francois Sebishyimno, Aline Umwizerwa, Nicaise Nsabimana, Cyprien Shyirambere, Temidayo Fadeli","doi":"10.1200/GO-25-00420","DOIUrl":"10.1200/GO-25-00420","url":null,"abstract":"","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500420"},"PeriodicalIF":3.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144882912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of Interactive, Patient-Centric Mobile Health Technology in Sub-Saharan Africa: A Scoping Review.","authors":"Kamaria L Lee, Susan Citonje Msadabwe-Chikuni, Dorothy C Lombe, Graciela M Nogueras Gonzalez, Pavitra P Krishnamani, Patrick P Carriere, Austin Huang, Lango Sichizya, Elizabeth Yu Chiao, Kate J Krause, Lilie L Lin, Susan K Peterson","doi":"10.1200/GO-25-00157","DOIUrl":"10.1200/GO-25-00157","url":null,"abstract":"<p><strong>Purpose: </strong>Although significant differences in health care outcomes remain between low-middle-income countries and high-income countries, access to mobile devices is comparable. Interactive, patient-centric mobile health (mHealth) technology interventions may mitigate the increasing cancer burden in sub-Saharan Africa. However, these interventions' distribution, efficacy, and feasibility in the region are unknown.</p><p><strong>Methods: </strong>We compiled literature on two-way, patient-centric mHealth technology in sub-Saharan Africa. We searched online databases for studies completed in sub-Saharan Africa with mHealth interventions (inception to July 23, 2024). Two authors independently completed title/abstract screening. Inclusion criteria were sub-Saharan African setting, age 13 years or older with any health condition, two-way mobile communication, and outcomes studies. Studies that passed title/abstract screening underwent full-text review by two independent authors. Discrepancies were resolved through consensus. Data extraction/review was completed using Covidence software and Microsoft Excel.</p><p><strong>Results: </strong>We retrieved 1,380 unique citations. After screening/review, the final sample size was 37. Randomized controlled trials were most common (n = 20). A plurality took place in Kenya. HIV was the most common condition (n = 30). Interventions included messages about medication/appointment adherence and patient status. Most studies (32 of 37 [86%]) had at least one positive finding. Study characteristics varied widely for those with positive findings, but using various message frequencies, or peer navigators/social supporters increased success. All studies with no positive findings were randomized controlled trials; four of the five were on HIV.</p><p><strong>Conclusion: </strong>Most two-way, patient-centric mHealth interventions in sub-Saharan Africa have been successful by at least one measure. Interventions have primarily been for patients with HIV. No studies have focused on cancer. With the increasing cancer burden in sub-Saharan Africa, an understanding of mHealth in oncologic settings is greatly needed.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500157"},"PeriodicalIF":3.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144794464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Head and Neck Cancer in Suriname: An Epidemiologic Review of Clinical and Pathologic Features of Patients Treated Between 2009 and 2021.","authors":"Sangeeta K Bisheshar, Els T M Dams, Mikel Chan, Lorian Slagter-Menkema, Harie Basdew, Tineke van der Sluis, Rabia N Mohamedradja-Taus, Dave P Ameerali, Ralph A E Akrum, Surya Sheorajpanday, Robert Mehilal, Rachel S van Leeuwaarde, Lot A Devriese, Boukje A C van Dijk, Stefan M Willems, Bert van der Vegt, Gerben E Breimer","doi":"10.1200/GO-25-00045","DOIUrl":"https://doi.org/10.1200/GO-25-00045","url":null,"abstract":"<p><strong>Purpose: </strong>This study investigates the incidence and clinicopathologic characteristics of head and neck cancer (HNC) in the Surinamese population, with an emphasis on the burden of human papillomavirus (HPV) and Epstein-Barr virus (EBV).</p><p><strong>Methods: </strong>Histologically confirmed HNC diagnosed between 2009 and 2021 were retrospectively collected from the Academic Hospital Paramaribo, the country's diagnostic pathology center. Additional clinical data were acquired from three other hospitals. Incidence rates were expressed as crude rates and age-adjusted World Standardized Rates per 100,000 population. Annual percentage changes (APCs) were calculated with Joinpoint regression software. HPV and EBV status were determined on pretreatment biopsies or resections of 263 patients from whom histopathologic material could be collected.</p><p><strong>Results: </strong>Of 364 patients, 279 (76.6%) were male. A substantial increase in HNC incidence was observed (2012-2019: annual percentage change 6.8%). Oral cavity carcinoma was most common in the Hindustani population, nasopharyngeal carcinoma (NPC) in the Maroon and Javanese populations, and laryngeal carcinoma (LC) in the Creole population. Patients with LC were more often smokers, whereas patients with oropharyngeal carcinoma (OPC) more often consumed alcohol. Most patients presented with advanced-stage disease at diagnosis (73.0%). Among 60 OPCs, 21 (35.0%) were HPV positive, and among 47 NPCs 43 (91.4%) were EBV positive.</p><p><strong>Conclusion: </strong>An increase in HNC incidence in Suriname has been observed that appears to be unrelated to a rise in OPC and is likely due to better diagnostic modalities and increase in the number of ear, nose, and throat specialists. Ethnic and lifestyle differences are seen in HNC primary tumor sites. The high proportion of advanced-stage disease at diagnosis highlights the urgent need to raise disease awareness and prioritize early detection to improve survival outcomes.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500045"},"PeriodicalIF":3.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144794461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Geriatric Assessment: ASCO Global Guideline.","authors":"Cristiane Decat Bergerot, Sarah Temin, Haydee C Verduzco-Aguirre, Matti S Aapro, Shabbir M H Alibhai, Zeba Aziz, María de la Concepción Pérez de Celis Herrero, Trinanjan Basu, Martine Extermann, Ravindran Kanesvaran, Bogda Koczwara, Kah Poh Loh, Elene Mariamidze, Alex Baleka Mutombo, Vanita Noronha, Grant R Williams, Enrique Soto-Perez-de-Celis","doi":"10.1200/GO-25-00276","DOIUrl":"https://doi.org/10.1200/GO-25-00276","url":null,"abstract":"<p><strong>Purpose: </strong>To guide clinicians and policymakers in global resource-constrained settings to assess the geriatric needs of patients older than 65 years with cancer when Maximal-setting guideline-recommended resources are unavailable.</p><p><strong>Methods: </strong>A multidisciplinary, multinational Expert Panel reviewed existing ASCO guidelines and conducted modified ADAPTE and formal consensus processes.</p><p><strong>Results: </strong>An ASCO resource-neutral guideline was adapted for resource-constrained settings, informing one round of formal consensus; recommendations received ≥75% agreement.</p><p><strong>Recommendations: </strong>The Expert Panel endorses the Maximal-setting guideline's overarching recommendation that end users utilize geriatric assessment (GA), including essential domains, to identify \"vulnerabilities or impairments not routinely captured in oncology assessment for all older patients over 65 years old with cancer.\" All care plans for patients with cancer over 65 years old receiving systemic therapy with GA-identified deficits should include GA-guided management. A geriatric evaluation should at a minimum include the use of a brief geriatric screening tool. Tools in the Practical Geriatric Assessment (PGA) are validated in multiple languages, but users may use more appropriate tools in some settings and languages, if they include the relevant guideline-specified domains. Maximal-resource settings of high-income countries have traditionally developed cutoffs for GA-identified deficits, but locally validated research and practice may inform differing cutoffs. If validated all-cause mortality prognosis tools do not adequately represent the setting, clinicians may use actuarial life-expectancy tables with quartiles of overall health status.<i>Additional information can be found at</i> www.asco.org/global-guidelines<i>. It is the view of ASCO that health care clinicians and health care system decision makers should be guided by the recommendations for the highest stratum of resources available. The guideline is intended to complement but not replace local guidelines.</i></p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500276"},"PeriodicalIF":3.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144954993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Banning Electronic Nicotine Delivery Systems in India.","authors":"Vaibhav Sahni, Abhishek Shankar","doi":"10.1200/GO-25-00242","DOIUrl":"https://doi.org/10.1200/GO-25-00242","url":null,"abstract":"","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500242"},"PeriodicalIF":3.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144794462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-Dose Abiraterone in Metastatic Castration-Resistant Prostate Cancer.","authors":"Julia Belone Lopes, Ana Elisa Sanches, Beatriz de Menezes Dobbert, Lorena Forner, João Pedro Homse Netto, Luiza Fadul, João Daniel Guedes, Fábio Fernandez, Daniel Vilarim Araujo","doi":"10.1200/GO-25-00132","DOIUrl":"https://doi.org/10.1200/GO-25-00132","url":null,"abstract":"<p><strong>Purpose: </strong>Abiraterone acetate (AA) is approved for prostate cancer at a standard dose of 1,000 mg fasting. Because of a significant food effect, a lower dose (250 mg with food-AA low dose [AALD]) shows similar efficacy at 75% lower cost. In Brazil, 80% of patients rely on the public health care system, which does not cover the standard dose. Hospital de Base has been using AALD since March 2021.</p><p><strong>Materials and methods: </strong>We retrospectively reviewed patients with metastatic castration-resistant prostate cancer (mCRPC) who received AALD at any treatment line, regardless of previous chemotherapy, between March 2021 and May 2023. The primary end point was prostate-specific antigen (PSA) response rate (RR; defined as a decrease of ≥50% in PSA level after 12 weeks of treatment). Secondary end points included time to treatment failure (TTF), overall survival (OS), and PSA RR ≥50% at nadir.</p><p><strong>Results: </strong>Ninety-six patients were included. Sixty-three patients (65.6%) received AALD in mCRPC first-line. After a median follow-up of 24.4 months, 53 patients (60.2%) achieved the primary end point, and 65 (69.9%) achieved a PSA reduction of ≥50% at nadir. Patients treated with AALD pre-docetaxel in the mCRPC had a higher PSA response at 12 weeks (68.3% <i>v</i> 40%, <i>P</i> = .015) and at nadir (76.1% <i>v</i> 53.8%, <i>P</i> = .036). First-line AALD was associated with better PSA responses. The median TTF was 7.9 months and the median OS was 20.6 months. Achieving a ≥50% PSA response at 12 weeks was associated with improved TTF (13.6 <i>v</i> 4.6 months, hazard ratio [HR] = 0.37, <i>P</i> < .001) and OS (28.9 <i>v</i> 12.2 months, HR = 0.44, <i>P</i> = .004).</p><p><strong>Conclusion: </strong>AALD showed meaningful efficacy and survival outcomes. We support AALD use, especially where standard dosing is unaffordable.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500132"},"PeriodicalIF":3.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144992708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Barriers to Immune Checkpoint Inhibitor Access for Patients With Cancer in Southeast Asia: Challenges and Policy Implications.","authors":"Adrian E Go, Frances Dominique V Ho, Erin Jay G Feliciano, Puneeth Iyengar, Imjai Chitapanarux, Chaiyut Charoentum, Nirmala Bhoo-Pathy, Nur Fadhlina Abdul Satar, Frederic Ivan L Ting, Edward Christopher Dee","doi":"10.1200/GO-25-00095","DOIUrl":"https://doi.org/10.1200/GO-25-00095","url":null,"abstract":"","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500095"},"PeriodicalIF":3.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12373009/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}